glenmark pharmaceuticals ltd
FabiFlu more economical, effective treatment option for COVID-19: Glenmark tells DGCI
Glenmark also denied making any claims that “favipiravir alone” is effective in treatment of mild-to-moderate COVID-19 patients
India's Glenmark to conduct trials for potential Covid19 drug
Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%
1 of 1